TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26599819

Group type: EXPERIMENTAL
Intervention: NASH females
Number of subjects: 70

Group type: COMPARATOR
Intervention: SS females
Number of subjects: 70

Group type: COMPARATOR
Intervention: Caucasian women with SS
Number of subjects: 70

Group type: COMPARATOR
Intervention: African American women with SS
Number of subjects: 70
Study: 26600201

Group type: EXPERIMENTAL
Intervention: Chronic musculoskeletal pain
Number of subjects: 1100

Group type: COMPARATOR
Intervention: Psychological wellbeing
Number of subjects: 1100

Group type: COMPARATOR
Intervention: Depression
Number of subjects: 1100

Group type: COMPARATOR
Intervention: Fatigue
Number of subjects: 1100

Group type: COMPARATOR
Intervention: Insomnia syndrome
Number of subjects: 1100

Group type: COMPARATOR
Intervention: Sleep quality
Number of subjects: 1100
Study: 26601643

Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity (MVPA)
Number of subjects: 1162

Group type: EXPERIMENTAL
Intervention: Waist circumference (WC) as a covariate
Number of subjects: 1162

Group type: EXPERIMENTAL
Intervention: Mediation analysis
Number of subjects: 1162
Study: 26602013

Group type: EXPERIMENTAL
Intervention: NCI-MPACT assay
Number of subjects: 38
Study: 26602014

Group type: EXPERIMENTAL
Intervention: Toremifene 180 mg daily
Number of subjects: 44
Study: 26602087

Group type: EXPERIMENTAL
Intervention: Structured personal diabetes care
Number of subjects: 179

Group type: COMPARATOR
Intervention: Routine diabetes care
Number of subjects: 179
Study: 26602164

Group type: EXPERIMENTAL
Intervention: Circulating fibrocytes during acute exacerbation (V1)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Circulating fibrocytes at 2 months after exacerbation (V2)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: High percentage of circulating fibrocytes during exacerbation (V1)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Percentage of fibrocytes at V2
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Fibrocytes collected from patients with COPD at V1
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Plerixafor (CXCR4 antagonist)
Number of subjects: 54
Study: 26602219

Group type: EXPERIMENTAL
Intervention: MR-Based Imaging Tests
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 26602490

Group type: EXPERIMENTAL
Intervention: Methacholine challenge testing (MCCT)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Exercise treadmill challenge (ETC)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Exercise treadmill challenge (ETC) with a cutoff level at 17% of forced expiratory volume in 1 second
Number of subjects: 101
Study: 26603283

Group type: EXPERIMENTAL
Intervention: Lung transplantation after ex vivo lung perfusion (EVLP)
Number of subjects: 10
Study: 26603536

Group type: EXPERIMENTAL
Intervention: lanreotide Autogel 120 mg every 4 weeks
Number of subjects: 90
Study: 26603828

Group type: EXPERIMENTAL
Intervention: Duloxetine (30 mg/day for 7 days, then 60 mg/day for 4 weeks)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study: 26603990

Group type: EXPERIMENTAL
Intervention: Renal denervation (RDN)
Number of subjects: 46
Study: 26604330

Group type: EXPERIMENTAL
Intervention: COPD
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Lung Cancer
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: OSAS
Number of subjects: 111

Group type: COMPARATOR
Intervention: Healthy Controls
Number of subjects: 111
Study: 26605292

Group type: EXPERIMENTAL
Intervention: Anisodamine
Number of subjects: 354

Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 354
Study: 26605506

Group type: EXPERIMENTAL
Intervention: Lower levels of CD4 CD38 T cells
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Higher levels of CD8 HLA-DR T cells
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Higher CD4 CD38 HLA-DR T cells levels
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Weight-for-age Z scores (WAZ)
Number of subjects: 111
Study: 26606398

Group type: EXPERIMENTAL
Intervention: Triple therapy (MTX plus sulfasalazine plus hydroxychloroquine)
Number of subjects: 416

Group type: COMPARATOR
Intervention: MTX monotherapy
Number of subjects: 416

Group type: COMPARATOR
Intervention: MTX plus etanercept
Number of subjects: 416
Study: 26606867

Group type: EXPERIMENTAL
Intervention: self-complementary AAV [scAAV]2(Y444,500,730F)-P1ND4v2 at low dose (5 × 10(9) vg)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: self-complementary AAV [scAAV]2(Y444,500,730F)-P1ND4v2 at medium dose (2.46 × 10(10) vg)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: self-complementary AAV [scAAV]2(Y444,500,730F)-P1ND4v2
Number of subjects: 5
Study: 26607424

Group type: EXPERIMENTAL
Intervention: EMA-approved dose
Number of subjects: 162

Group type: COMPARATOR
Intervention: FDA-approved dose
Number of subjects: 162
Study: 26607940

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Laparoscopic adjustable gastric banding (LAGB)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Both RYGB and LAGB
Number of subjects: 25
Study: 26607943

Group type: EXPERIMENTAL
Intervention: Top tertile of glycemic index (GI)
Number of subjects: 3363

Group type: EXPERIMENTAL
Intervention: Higher glycemic load (GL) values
Number of subjects: 3363

Group type: EXPERIMENTAL
Intervention: Greater GI in women
Number of subjects: 3363
Study: 26607977

Group type: EXPERIMENTAL
Intervention: Nomogram-based adaptation of radiotherapy target volumes for ECE
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Nomogram-based adaptation of radiotherapy target volumes for SVI
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Nomogram-based adaptation of radiotherapy target volumes for LNI
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Compliance with trial contouring protocol
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Compliance with small bowel contouring
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Compliance with dose constraints for target volumes
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Compliance with dose constraints for OAR
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Acute toxicity assessment
Number of subjects: 27
Study: 26608460

Group type: EXPERIMENTAL
Intervention: Lateral flow test (LFT) with G12 monoclonal antibody for gluten immunogenic peptides (GIP)
Number of subjects: 58
Study: 26608642

Group type: EXPERIMENTAL
Intervention: Potentially inappropriate prescribing (PIP) assessment tools applied to population-wide health administrative data
Number of subjects: 2000000
Study: 26608976

Group type: EXPERIMENTAL
Intervention: OROS-MPH (18 mg, 36 mg, or 54 mg)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Non-ADHD group (control)
Number of subjects: 153
Study: 26609168

Group type: EXPERIMENTAL
Intervention: Zinc deficiency risk assessment using stunting rates, dietary zinc intake, and plasma zinc concentration.
Number of subjects: 598

Group type: EXPERIMENTAL
Intervention: Plasma zinc concentration (PZn) measurement.
Number of subjects: 598

Group type: EXPERIMENTAL
Intervention: Height-for-age z scores (HAZ) measurement.
Number of subjects: 598
Study: 26610172

Group type: EXPERIMENTAL
Intervention: Group drumming intervention, details on dosage and duration not available
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group, details not available
Number of subjects: 0
Study: 26611339

Group type: EXPERIMENTAL
Intervention: Iontophoresis system (IPS) in conjunction with tube delivery system (TDS) for tube placement
Number of subjects: 70
Study: 26612014

Group type: EXPERIMENTAL
Intervention: ledipasvir/sofosbuvir (LDV/SOF) (90 mg/400 mg) daily for 12 weeks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: ledipasvir/sofosbuvir (LDV/SOF) + GS-9451 (80 mg/day) daily for 6 weeks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: ledipasvir/sofosbuvir (LDV/SOF) + GS-9669 (500 mg twice daily) for 6 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Recent drug use
Number of subjects: 60

Group type: COMPARATOR
Intervention: Controlled psychiatric disease or symptoms of depression
Number of subjects: 60
Study: 26612072

Group type: EXPERIMENTAL
Intervention: Autocalibrated semi-invasive pulse contour analysis (CIPFX)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Transpulmonary thermodilution (CITPTD)
Number of subjects: 65
Study: 26612321

Group type: EXPERIMENTAL
Intervention: Neoadjuvant concurrent chemoradiotherapy with hematopoietical bone marrow sparing
Number of subjects: 35
Study: 26612576

Group type: EXPERIMENTAL
Intervention: Bi-phasic injectable ceramic bone substitute (CERAMENT™ BONE VOID FILLER)
Number of subjects: 14
Study: 26612701

Group type: COMPARATOR
Intervention: PPI (Proton Pump Inhibitors)
Number of subjects: 10116

Group type: COMPARATOR
Intervention: H2 RA (H2-receptor antagonists)
Number of subjects: 10116

Group type: EXPERIMENTAL
Intervention: Unexposed infants
Number of subjects: 10116

Group type: EXPERIMENTAL
Intervention: PPI cohort
Number of subjects: 10116

Group type: EXPERIMENTAL
Intervention: H2 RA cohort
Number of subjects: 10116
Study: 26612870

Group type: EXPERIMENTAL
Intervention: 300 mg posaconazole (as tablets) once daily (twice daily on day 1) for up to 28 days
Number of subjects: 210
Study: 26612873

Group type: EXPERIMENTAL
Intervention: Intravesicular cidofovir (2.5-5 mg/kg in 50-100 mL of normal saline) administered via transurethral catheter after oral probenecid (2 g) for up to 2 h of dwell time.
Number of subjects: 6
Study: 26612880

Group type: EXPERIMENTAL
Intervention: Pacemaker implantation
Number of subjects: 281

Group type: COMPARATOR
Intervention: No pacemaker (observed by ILR)
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Negative tilt test (TT)
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Positive tilt test (TT)
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Carotid sinus massage (CSM)
Number of subjects: 281
Study: 26612979

Group type: EXPERIMENTAL
Intervention: Dabigatran 220 mg once daily after switching from enoxaparin 40 mg for thromboprophylaxis
Number of subjects: 168

Group type: COMPARATOR
Intervention: Enoxaparin 40 mg for thromboprophylaxis
Number of subjects: 168
Study: 26614268

Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg once daily for 4 weeks
Number of subjects: 32
Study: 26614807

Group type: COMPARATOR
Intervention: Gene expression signature consisting of LRRN3, SASH1, PALLD, RGL1, TNFRSF17, CDKN1C, IGJ, RRM2, ID3, SERPING1, FUCA1; measured in whole blood.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cigarette smoke exposure in mice.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PCR-based assay derived from the gene signature.
Number of subjects: 0
Study: 26614966

Group type: EXPERIMENTAL
Intervention: Disulfiram 500 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Disulfiram 1000 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Disulfiram 2000 mg
Number of subjects: 30
Study: 26615020

Group type: EXPERIMENTAL
Intervention: TMZ/veliparib
Number of subjects: 28

Group type: COMPARATOR
Intervention: TMZ alone
Number of subjects: 28
Study: 26615061

Group type: EXPERIMENTAL
Intervention: Hydroxyurea treatment with a pharmacokinetic-guided dosing strategy, initial dose of 20 mg/kg oral dose.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pharmacokinetic-guided dosing strategy
Number of subjects: 0
Study: 26615402

Group type: EXPERIMENTAL
Intervention: High-fat diet (HFD: 55% fat/25% saturated fat/27% carbohydrate)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Low-fat diet (LFD: 20% fat/8% saturated fat/62% carbohydrate)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Low-fat diet (LFD)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: High-fat diet (HFD)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 20
Study: 26615857

Group type: EXPERIMENTAL
Intervention: FOLFIRI plus cetuximab
Number of subjects: 98
Study: 26616030

Group type: EXPERIMENTAL
Intervention: Guideline-directed medical therapy (GDMT) plus revascularization (percutaneous coronary intervention or coronary artery bypass graft surgery)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Guideline-directed medical therapy (GDMT) alone
Number of subjects: 0
Study: 26618098

Group type: EXPERIMENTAL
Intervention: Convalescent plasma therapy (2 units)
Number of subjects: 20
Study: 26618119

Group type: EXPERIMENTAL
Intervention: Neuramis Deep
Number of subjects: 67

Group type: COMPARATOR
Intervention: Restylane
Number of subjects: 67
Study: 26618534

Group type: EXPERIMENTAL
Intervention: Small vessel disease (SVD) noted on baseline MRI
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Presence of SVD
Number of subjects: 451

Group type: COMPARATOR
Intervention: Control group (patients without SVD)
Number of subjects: 451
Study: 26619773

Group type: EXPERIMENTAL
Intervention: Clozapine treatment, dosage and duration not specified
Number of subjects: 0
Study: 26619834

Group type: EXPERIMENTAL
Intervention: Vorinostat 400 mg plus bortezomib 1.3 mg/m(2)
Number of subjects: 7
Study: 26620049

Group type: EXPERIMENTAL
Intervention: Vildagliptin 50 mg bid
Number of subjects: 156

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study: 26620200

Group type: EXPERIMENTAL
Intervention: Smartphone-based telesonography for echocardiography
Number of subjects: 100

Group type: COMPARATOR
Intervention: LCD monitor for echocardiography
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Smartphone-based telesonography for abdominal ultrasonography
Number of subjects: 100

Group type: COMPARATOR
Intervention: LCD monitor for abdominal ultrasonography
Number of subjects: 100
Study: 26620715

Group type: EXPERIMENTAL
Intervention: F/B-EVAR
Number of subjects: 168

Group type: COMPARATOR
Intervention: Self-expanding stents
Number of subjects: 168
Study: 26621025

Group type: EXPERIMENTAL
Intervention: Expressive writing (N=15 patients, 8 caregivers)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Neutral writing (N=12 patients, 6 caregivers)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Cortisol awakening response (CAR)
Number of subjects: 41
Study: 26621395

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) and leucocyte counts assessment
Number of subjects: 226

Group type: COMPARATOR
Intervention: Surgeons' initial diagnosis
Number of subjects: 226
Study: 26621394

Group type: EXPERIMENTAL
Intervention: Subtotal hysterectomy
Number of subjects: 501

Group type: COMPARATOR
Intervention: Total hysterectomy
Number of subjects: 501
Study: 26621580

Group type: EXPERIMENTAL
Intervention: Quercetin (up to 5 g daily)
Number of subjects: 30
Study: 26622643

Group type: EXPERIMENTAL
Intervention: Belinostat in combination with cisplatin, doxorubicin, and cyclophosphamide
Number of subjects: 1
Study: 26624926

Group type: EXPERIMENTAL
Intervention: Homozygous GG genotype of PSMD13 rs3817629
Number of subjects: 621

Group type: EXPERIMENTAL
Intervention: PSMD9 rs1043307
Number of subjects: 621
Study: 26625169

Group type: EXPERIMENTAL
Intervention: Brief Smell Identification Test (BSIT)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Smell Identification Test (SIT)
Number of subjects: 183
Study: 26625449

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation of 7000 IU/day
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation of 4000 IU/day
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (both doses)
Number of subjects: 44
Study: 26626272

Group type: EXPERIMENTAL
Intervention: Adductor squeeze test (90° hip flexion)
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: MRI findings
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Clinical diagnosis of injured anatomical structure
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Overall cohort analysis
Number of subjects: 382
Study: 26627079

Group type: EXPERIMENTAL
Intervention: Volasertib (300 mg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Volasertib (350 mg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Volasertib (200-350 mg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Volasertib
Number of subjects: 15
Study: 26627107

Group type: EXPERIMENTAL
Intervention: E/C/F/TAF (elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg, TAF 10 mg)
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: E/C/F/TAF
Number of subjects: 242
Study: 26628448

Group type: EXPERIMENTAL
Intervention: STAMP scoring system
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Modified STAMP
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: STAMP
Number of subjects: 60
Study: 26628565

Group type: EXPERIMENTAL
Intervention: FVC/FENO ratio
Number of subjects: 1529

Group type: EXPERIMENTAL
Intervention: FEV1/FENO ratio
Number of subjects: 1529

Group type: EXPERIMENTAL
Intervention: FEF25-75%/FENO ratio
Number of subjects: 1529

Group type: EXPERIMENTAL
Intervention: FENO/FVC ratio
Number of subjects: 1529

Group type: EXPERIMENTAL
Intervention: FENO/FEV1 ratio
Number of subjects: 1529

Group type: EXPERIMENTAL
Intervention: FENO/FEF25-75% ratio
Number of subjects: 1529

Group type: EXPERIMENTAL
Intervention: FEF25-75%/FENO and FENO/FEF25-75% values
Number of subjects: 1529

Group type: EXPERIMENTAL
Intervention: FVC/FENO, FEV1/FENO, and FEF25-75%/FENO
Number of subjects: 1529

Group type: EXPERIMENTAL
Intervention: New lung function/lung inflammation ratios
Number of subjects: 1529
Study: 26628614

Group type: EXPERIMENTAL
Intervention: ACP-501 (recombinant human LCAT) at 0.9 mg/kg
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: ACP-501 (recombinant human LCAT) at 3.0 mg/kg
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: ACP-501 (recombinant human LCAT) at 9.0 mg/kg
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: ACP-501 (recombinant human LCAT) at 13.5 mg/kg
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: ACP-501 (recombinant human LCAT)
Number of subjects: 4
Study: 26628838

Group type: EXPERIMENTAL
Intervention: EVL plus somatostatin (250 mcg/hr)
Number of subjects: 61

Group type: COMPARATOR
Intervention: EVL plus placebo
Number of subjects: 61
Study: 26629367

Group type: EXPERIMENTAL
Intervention: Infliximab treatment
Number of subjects: 86
Study: 26630396

Group type: EXPERIMENTAL
Intervention: Pulmonary vasodilator therapy (phosphodiesterase-5 inhibitors, 88% at entry, 87% after 1 year)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Pulmonary vasodilator therapy (phosphodiesterase-5 inhibitors)
Number of subjects: 151
Study: 26630918

Group type: EXPERIMENTAL
Intervention: PAC-1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PAC-1 derivatives
Number of subjects: 0
Study: 26631084

Group type: EXPERIMENTAL
Intervention: Long-term ECG monitoring using an implantable loop recorder for 12 months.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy volunteers (control group) matched by age and sex.
Number of subjects: 0
Study: 26631428

Group type: EXPERIMENTAL
Intervention: Lurasidone 20, 40, 80, 120, and 160 mg/d
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lurasidone doses <120 mg/d
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lurasidone (multiple doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lurasidone (adverse events)
Number of subjects: 0
Study: 26631691

Group type: EXPERIMENTAL
Intervention: Oral moisturizing jelly (OMJ) used for 2 weeks
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Oral moisturizing jelly (OMJ) used for 1 month
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Oral moisturizing jelly (OMJ)
Number of subjects: 118
Study: 26631736

Group type: COMPARATOR
Intervention: Ob-MSCs (mesenchymal stem cells from infants born to obese mothers)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Ob-MSCs
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Lithium chloride inhibition of GSK-3β
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Adipogenic differentiating cells
Number of subjects: 29
Study: 26632544

Group type: EXPERIMENTAL
Intervention: sorafenib
Number of subjects: 0

Group type: COMPARATOR
Intervention: brivanib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: oxaliplatin-based or gemcitabine-based regimen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: capecitabine
Number of subjects: 0

Group type: COMPARATOR
Intervention: other treatments
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: antiviral treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: nutritional treatment
Number of subjects: 0
Study: 26632545

Group type: EXPERIMENTAL
Intervention: Immunotherapy strategies including vaccines, adaptive therapy, immune checkpoint blockades, and cytokines.
Number of subjects: 0
Study: 26632639

Group type: EXPERIMENTAL
Intervention: Patients with schizophrenia
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Patients with impaired QoL
Number of subjects: 106

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 106
Study: 26632823

Group type: EXPERIMENTAL
Intervention: ART delivery
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: ART delivery with local salaries and core laboratory tests
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: ART delivery with lower salaries and lowest ART prices
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Maximally efficient scale-up model
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Cost breakdown
Number of subjects: 197
Study: 26632880

Group type: EXPERIMENTAL
Intervention: Chemotherapy-induced pain (CHIP)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Present pain experiences
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Future pain expectations
Number of subjects: 15
Study: 26633472

Group type: EXPERIMENTAL
Intervention: Replacing animal protein with plant protein (median level of ~35% of total protein per day)
Number of subjects: 280
Study: 26633622

Group type: EXPERIMENTAL
Intervention: TNF inhibitors
Number of subjects: 55
Study: 26634245

Group type: EXPERIMENTAL
Intervention: SNPs at the 15q25 locus (containing CHRNA3/5, AGPHD1, IREB2, CHRNB4)
Number of subjects: 9919

Group type: EXPERIMENTAL
Intervention: Genomic region on chromosome 4 (upstream of HHIP)
Number of subjects: 9919

Group type: EXPERIMENTAL
Intervention: Chromosome 1 (TGFB2)
Number of subjects: 9919

Group type: EXPERIMENTAL
Intervention: Chromosome 9 (DBH)
Number of subjects: 9919

Group type: EXPERIMENTAL
Intervention: Chromosome 19 (CYP2A6/7)
Number of subjects: 9919

Group type: EXPERIMENTAL
Intervention: Chromosome 4 (FAM13A)
Number of subjects: 9919

Group type: EXPERIMENTAL
Intervention: Chromosome 11 (MMP3/12)
Number of subjects: 9919

Group type: EXPERIMENTAL
Intervention: Chromosome 14 (RIN3)
Number of subjects: 9919